

Irpagratinib

Chemical Properties

CAS No. : 2230974-62-4

Formula: C₂₈H₃₂F₂N₆O₅


Molecular Weight: 570.59

Storage:

Store at low temperature, Keep away from moisture,
Keep away from direct sunlight

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	Irpagratinib (ABSK011) is an orally active and highly effective FGFR4 antagonist with antitumor activity, inhibiting FGFR4 autophosphorylation and blocking FGFR4 signaling to downstream pathways. It is used in studies of gastrointestinal diseases and cancer.
Targets(IC50)	FGFR
In vitro	Irpagratinib inhibits FGFR4 with IC ₅₀ < 10 nM and shows at least 50-fold selectivity against other FGFR kinases. Irpagratinib has the ability to irreversibly modify Cys552. [1]
In vivo	Oral Irpagratinib strongly inhibited the growth of subcutaneous xenograft tumors dependent on FGFR4 activity and induced their regression. [1]

Solubility Information

Solubility	DMSO: 80 mg/mL (140.21 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (5.78 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

A DRUG SCREENING EXPERT

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.7526 mL	8.7629 mL	17.5257 mL
5 mM	0.3505 mL	1.7526 mL	3.5051 mL
10 mM	0.1753 mL	0.8763 mL	1.7526 mL
50 mM	0.0351 mL	0.1753 mL	0.3505 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Chen Z. Abstract LB-272: Discovery and characterization of a novel FGFR4 Inhibitor for the treatment of hepatocellular carcinoma[J]. Cancer Research, 2018, 78(13_Supplement): LB-272-LB-272.

Huang H, et al. Improvements in advanced hepatocellular carcinoma to repeat implementation of primary protocol after cancer progression occurs following sequential systemic therapy and a clinical trial: A case report. Medicine (Baltimore). 2024 May 10;103(19):e38138.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481